1. Home
  2. VERI vs CRDF Comparison

VERI vs CRDF Comparison

Compare VERI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veritone Inc.

VERI

Veritone Inc.

HOLD

Current Price

$0.79

Market Cap

80.2M

Sector

Technology

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.04

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERI
CRDF
Founded
2014
1999
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.2M
86.8M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
VERI
CRDF
Price
$0.79
$1.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$7.00
$9.63
AVG Volume (30 Days)
4.5M
699.6K
Earning Date
04-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
$92,637,000.00
$365,993.00
Revenue This Year
$52.20
N/A
Revenue Next Year
$3.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$0.76
$0.76
52 Week High
$9.42
$3.31

Technical Indicators

Market Signals
Indicator
VERI
CRDF
Relative Strength Index (RSI) 31.82 54.44
Support Level N/A $0.87
Resistance Level $1.56 $1.13
Average True Range (ATR) 0.09 0.07
MACD -0.03 0.02
Stochastic Oscillator 3.53 77.83

Price Performance

Historical Comparison
VERI
CRDF

About VERI Veritone Inc.

Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: